Cardiovascular Systems, Inc. (CSII) Reached 1-Year High on Jun, 27

June 27, 2018 - By Julia Strobel

During Q1 2018 the big money sentiment decreased to 0.86. That’s change of 0.16, from 2017Q4’s 1.02. 17 investors sold all, 42 reduced holdings as Cardiovascular Systems, Inc. ratio is negative. 34 increased holdings while 17 funds bought holdings. Funds hold 26.24 million shares thus 0.31% more from 2017Q4’s 26.16 million shares.
Ameriprise Fincl holds 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII) or 66,217 shs. Gabelli Funds owns 240,000 shs. Ameritas Investment owns 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 2,803 shs. Consonance Management Lp has 0.89% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). Vanguard Grp Inc owns 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 1.52 million shs. Prelude Ltd Com owns 3,360 shs or 0.01% of their US capital. Ubs Asset Mgmt Americas Incorporated holds 404 shs or 0% of its capital. Wellington Group Inc Llp has invested 0.01% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Sterling Capital Mngmt Ltd Liability Com owns 75,010 shs for 0.02% of their capital. Hussman Strategic Advisors holds 50,000 shs or 0.3% of its capital. First Mercantile Tru Company has invested 0.06% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Alliancebernstein Lp reported 41,420 shs stake. Fmr Ltd Liability accumulated 0% or 179,800 shs. The New Jersey-based State Of New Jersey Common Pension Fund D has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Ontario – Canada-based Manufacturers Life Company The has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII).

A one-year high was broke into by Cardiovascular Systems, Inc. (NASDAQ:CSII). Today’s stock price was $33.68. It’s 4.00 % above our $35.02. On Jun, 27 it was announced by The company has $1.12 billion MC. $44.80 million more could be NASDAQ:CSII valuation at $35.02 share price.

CSII is hitting $33.675 during the last trading session, after increased 9.41%.Cardiovascular Systems, Inc. is uptrending after having risen 0.43% since June 27, 2017. CSII has 295,464 volume or 38.30% up from normal. The stock underperformed the S&P 500 by 12.14%.

Cardiovascular Systems, Inc. (NASDAQ:CSII)’s earnings report is awaited on August, 1., according to RTT. This year’s EPS analyst estimate is awaited to be $0.06. That is 200.00 % up compareed to $0.02 EPS for last year. This could be $2.00 million profit for CSII assuming the current $0.06 EPS will become reality. Wall Street now predicts 500.00 % EPS growth despite Cardiovascular Systems, Inc. last quarter’s EPS of $0.01.

More recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were released by, and The first one has “Cardiovascular Systems gets two-notch upgrade at BAML” as a title and was released on June 27, 2018. The next is “Detailed Research: Economic Perspectives on LSC Communications, Cardiovascular, RPX, Nustar Energy, LSB …” on June 19, 2018. And last was released on June 27, 2018, called “BofA/Merrill Lynch Double Upgrades Cardiovascular Systems (CSII) to Buy”.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States.The firm is worth $1.12 billion. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.Currently it has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: